Tocainide

Cat. No.:	HY-B1798				
CAS No.:	41708-72-9				
Molecular Formula:	C ₁₁ H ₁₆ N ₂ O				
Molecular Weight:	192.26				
Target:	Sodium Channel				
Pathway:	Membrane Transporter/Ion Channel				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		


SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	5.2013 mL	26.0065 mL	52.0129 mL	
	5 mM	1.0403 mL	5.2013 mL	10.4026 mL	
	10 mM	0.5201 mL	2.6006 mL	5.2013 mL	

BIOLOGICAL ACTIV	
Description	Tocainide hydrochloride is an orally activesodium channel blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is a primary amine analog of lidocaine, can be used for the treatment of tinnitus ^{[1][2]} .
IC ₅₀ & Target	IC50: sodium channel ^[1]
In Vivo	Tocainide (100 mg/kg) effectively suppresses ventricular ectopic activity in unanesthetized dogs with coronary occlusion. Termination of tocainide infusion in both digitalis toxicity and coronary occlusion models results in prompt return of ventricular ectopic activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Alpert JS, et al. Chemistry, pharmacology, antiarrhythmic efficacy and adverse effects of tocainide hydrochloride, an orally active structural analog of lidocaine.





Pharmacotherapy. 1983 Nov-Dec;3(6):316-23.

[2]. De Luca A, et al. Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol Pharmacol. 2003 Oct;64(4):932-45.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA